Selected article for: "low affinity and mab therapy"
Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future
  • Document date: 2017_3_28
    • ID: 0fegsm1v_110
    Snippet: Fc-engineered antibodies improve the ADCC/ADCP potential and target CD19, CD20, CD40, and Her2. Consequently, they enhance the therapeutic potential of mAbs. NK cells are exclusive in exhibiting low-affinity activating FcγRIIIa (CD16), and no inhibitory antibody receptors, featuring a substantial role in ADCC. Several studies have established a link between activating Fc receptors and the efficacy of mAb therapy using mouse tumor models (Romain .....
    Document: Fc-engineered antibodies improve the ADCC/ADCP potential and target CD19, CD20, CD40, and Her2. Consequently, they enhance the therapeutic potential of mAbs. NK cells are exclusive in exhibiting low-affinity activating FcγRIIIa (CD16), and no inhibitory antibody receptors, featuring a substantial role in ADCC. Several studies have established a link between activating Fc receptors and the efficacy of mAb therapy using mouse tumor models (Romain et al., 2014) .

    Search related documents:
    Co phrase search for related documents
    • antibody receptor and mAb therapy: 1
    • antibody receptor and mAb therapy efficacy: 1
    • antibody receptor and NK cell: 1, 2, 3, 4
    • antibody receptor and therapeutic potential: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • Fc receptor and mAb therapy: 1
    • Fc receptor and mAb therapy efficacy: 1
    • Fc receptor and NK cell: 1, 2, 3, 4, 5, 6, 7
    • Fc receptor and therapeutic potential: 1, 2, 3, 4, 5, 6, 7
    • inhibitory antibody receptor and therapeutic potential: 1
    • low affinity and mAb therapy: 1
    • low affinity and NK cell: 1, 2, 3
    • low affinity and therapeutic potential: 1, 2, 3, 4, 5, 6
    • low affinity and tumor model: 1
    • mAb therapy and NK cell: 1, 2
    • mAb therapy and therapeutic potential: 1
    • mAb therapy and tumor model: 1
    • mAb therapy efficacy and NK cell: 1
    • mAbs therapeutic potential and therapeutic potential: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • mouse tumor model and therapeutic potential: 1, 2